Clinical Trial Update: A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia [Phase 2]

View source ↗

Summary

Phase 2 single-arm pilot study evaluating low-dose rituximab plus standard prednisone for idiopathic autoimmune hemolytic anemia; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Cold Agglutinin Disease
• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• PREDNISONE (Prednisone)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Conditions: Autoimmune Hemolytic Disease (Cold Type) (Warm Type) | Phase 2 | Status: COMPLETED